🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Successfully matching blood and tissue samples from clinical trials labeled with a 16 character biospecimen ID, to study participants identified by a 10 character trial ID.

I am so appreciative that my dear patient Adam was willing to come out to Fenway Park for the WEEI / NESN The Jimmy Fund Radio-Telethon on his wedding anniversary (!) to raise awareness around testicular cancer and to support research at Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology. #KCANCER

Great job Dana Rathkopf ESMO - Eur. Oncology presenting on our new AR degrader! Now published in Annals of Oncology for more details: annalsofoncology.org/article/S0923-… DCI Center for Prostate & Urologic Cancers The PCCTC Duke Cancer MSK Oncology Updates

Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in European Urology Oncology: sciencedirect.com/science/articl…

Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion. clinicaltrials.gov/study/NCT06463…

Thank you Dana-Farber for this recognition, and to Toni Choueiri, MD for your guidance and advocacy. I appreciate all the support from mentors, collaborators, colleagues, research staff, and trial participants as we try to continue to advance care of patients with GU cancers.

Thank you Dana-Farber News for highlighting this work conducted by talented CRC Autumn Gagnon demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping.

So proud for Autumn Gagnon to have the opportunity to present her work on testosterone suppression and recovery with abiraterone after early LHRH-A discontinuation. We are excited that she has chosen to apply to medical school! Dana-Farber Lank Center for Genitourinary Oncology

🗣️Prostate Cancer Rapid Oral Abstracts #GU25 Dr Abdenour Nabid presenting Ab310 "Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial." N = 630 RT + ADT 18 mo

🗣️Prostate Cancer Rapid Oral Abstracts #GU25 Dr Michael Schweizer presenting Ab138 "Mevrometostat (PF-06821497), an (EZH2) inhibitor, in combination with ENZA in patients with (mCRPC): A randomized dose-expansion study." N = 81 mCRPC prior ABI, <1 chemo (~45%), PD per PCWG3

We are so honored to have you join us, Dr. Bishoy M. Faltas, and we are really looking forward to your talk on this fascinating topic!

Prostate cancer at #ASCO25: Talazoparib + tazemetostat showed expected bone marrow suppression & limited benefit in pre-treated, biomarker-unselected patients. Research underway to ID those most likely to respond. Atish Choudhury, MD PhD Dana-Farber Lank Center for Genitourinary Oncology

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapies Unplugged: Is It Time to Break up With ADT? | Atish D. Choudhury dissects BULLSEYE Ph III insights on ^177Lu‑PSMA‑617 in oHSPC—delaying ADT, QoL benefits, and safety considerations. By our

The whole team at the Gelb Center for Translational Research Dana-Farber Lank Center for Genitourinary Oncology are so proud of Ilana's poster presentation and many other achievements!

Thank you to the discussant Rahul Aggarwal and Jordan Ciuro, MD for highlighting A-DREAM for treatment interruption for pts with PSA < 0.2 after 18-24 mo of ADT+ARPI, with primary endpoint of 18 months treatment-free with testosterone recovery. Dana-Farber Lank Center for Genitourinary Oncology Stephanie Berg Alliance for Clinical Trials in Oncology

Thank you UroToday.com and Rashid K. Sayyid for this comprehensive writeup of my talk. ADT-free strategies certainly warrant further study, but novel treatments also bring the opportunity to explore multimodality strategies with curative intent. Dana-Farber Lank Center for Genitourinary Oncology Alicia Morgans, MD, MPH